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Angiogenesis is an essential physiological process and an important factor in disease pathogenesis. 
However, its exploitation as a clinical target has achieved limited success and novel molecular targets 
are required. Although heme oxygenase-1 (HO-1) acts downstream of vascular endothelial growth 
factor (VEGF) to modulate angiogenesis, knowledge of the mechanisms involved remains limited. We 
set out identify novel HO-1 targets involved in angiogenesis. HO-1 depletion attenuated VEGF-induced 
human endothelial cell (EC) proliferation and tube formation. The latter response suggested a role for 
HO-1 in EC migration, and indeed HO-1 siRNA negatively affected directional migration of EC towards 
VEGF; a phenotype reversed by HO-1 over-expression. EC from Hmox1−/− mice behaved similarly. 
Microarray analysis of HO-1-depleted and control EC exposed to VEGF identified cyclins A1 and E1 as 
HO-1 targets. Migrating HO-1-deficient EC showed increased p27, reduced cyclin A1 and attenuated 
cyclin-dependent kinase 2 activity. In vivo, cyclin A1 siRNA inhibited VEGF-driven angiogenesis, a 
response reversed by Ad-HO-1. Proteomics identified structural protein vimentin as an additional 
VEGF-HO-1 target. HO-1 depletion inhibited VEGF-induced calpain activity and vimentin cleavage, 
while vimentin silencing attenuated HO-1-driven proliferation. Thus, vimentin and cyclins A1 and E1 
represent VEGF-activated HO-1-dependent targets important for VEGF-driven angiogenesis.
Although angiogenesis is fundamental to physiological processes in the adult, including wound healing and 
the menstrual cycle, it is also integral to the pathogenesis of atherosclerosis, diabetic retinopathy, inflammatory 
arthritis and malignant diseases. Investigation of angiogenesis as a potential therapeutic target has included strat-
egies to either inhibit or enhance neovascularisation. However, clinically-derived benefit is relatively limited and 
different approaches and novel molecular targets are being sought1. Although the anti-oxidant, anti-apoptotic and 
anti-inflammatory enzyme heme oxygenase-1 (HO-1) has an established role in angiogenesis, understanding of 
associated downstream molecular mechanisms remains incomplete and the therapeutic potential of HO-1 mini-
mally explored (reviewed in refs 2–4).
Extensive study has revealed a context-dependent effect of HO-1 activity in angiogenesis2,4. We initially pro-
posed a dual role for HO-1 in chronic inflammation where HO-1 activity inhibits leukocyte migration, while pro-
moting vascular endothelial growth factor (VEGF)-driven reparative angiogenesis5,6. Similar observations have 
been made in other settings7,8, and through the demonstration that HO-1 activity is protective against inflam-
matory arthritis9–12. HO-1 over-expression promotes endothelial cell (EC) proliferation and enhances develop-
ment of endothelial tubules on Matrigel13. Subsequent pharmacological and molecular targeting experiments 
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revealed the importance of HO-1 activity in growth-factor driven EC cell cycle progression, proliferation and 
capillary formation5,14,15. Hmox-1-deficient mice exhibit reduced endothelial proliferative responses to growth 
factors, attenuated tube formation and impaired wound healing16,17. In addition, Hmox-1−/− EC are more sus-
ceptible to pro-apoptotic stimuli than Hmox-1+/+ EC18. Thus, increased resistance to apoptosis may add to the 
pro-angiogenic influence of HO-1.
A complex relationship exists between VEGF and HO-1. First, VEGF synthesis can be altered by HO-1 activ-
ity. HO-1 inhibition impairs VEGF release in response to prostaglandin J2 (PGJ2), hemin and hypoxia, while 
increased HO-1 activity or delivery of carbon monoxide (CO) enhances VEGF release19–21. Second, VEGF is able 
to increase HO-1 expression and activity5,22, suggesting the presence of a positive feedback pathway and endoge-
nous amplification6,23. These data have been reinforced and extended by two recent studies. In the first, treatment 
of EC with VEGF or stromal cell-derived factor-1α (SDF-1α ) led to translocation of nuclear factor E2-related 
factor 2 (Nrf2) and induction of HO-1. Subsequent experiments confirmed the importance of Nrf2 activation for 
angiogenesis24. Meanwhile, the hypoxic induction of miR-101 regulates angiogenesis by binding to cullin 3 and 
stabilising Nrf2, leading to activation of an HO-1/VEGF/endothelial nitric oxide synthase (eNOS) pathway25.
The next challenge is to identify the target genes acting downstream of HO-1 and its products, and ultimately 
to determine whether these pathways might be targeted therapeutically. Analysis of HO-1 enzymatic product CO 
has shed some light and suggests CO may contribute to the proliferative and pro-migratory actions of HO-114,20,26. 
CO rapidly activates Ras homolog gene family member A (RhoA) leading to Akt and eNOS phosphorylation 
and increased nitric oxide biosynthesis26. The importance of RhoA implies a role for cytoskeletal and cell cycle 
regulators. Indeed, the pro-angiogenic actions of SDF-1α are mediated at least in part through activation of HO-1 
and CO release, with subsequent phosphorylation of the cytoskeletal regulator vasodilator-stimulated phosphop-
rotein (VASP)16. Delivery of CO reversed the angiogenic defects seen in SDF-1α -treated Hmox1−/−EC and aor-
tic rings16. However, context-dependent, cell-type specific actions have also been reported, with HO-1 and CO 
able to either enhance or inhibit angiogenesis under specific circumstances14,20,26,27, particularly in the tumour 
microvasculature28. These findings, which likely reflect differences in the local microenvironment, including the 
presence or absence of individual growth factors and pro-inflammatory responses, serve to further emphasise 
the dual role of HO-1 in different settings6, and the need for improved understanding of molecular mechanisms.
In the current study, a gain and loss of function approach employed targeted genomic and proteomic tech-
niques to identify HO-1 downstream targets that regulate angiogenesis. The data generated demonstrate that 
cyclins A1 and E1, and the structural protein vimentin, are HO-1-dependent proteins that play an important role 
in VEGF-driven angiogenic responses including cell proliferation and migration.
Materials and Methods
Reagents. Antibodies against Bcl-2, cyclin A1, proliferating cell nuclear antigen (PCNA) and retinoblastoma 
(Rb) protein were purchased from Santa Cruz Biotechnology (California, USA). Anti-HO-1 and anti-HO-2 were 
from Stressgen (Exeter, UK). Anti-phospho RbThr821 and anti-vimentin were from Invitrogen (Paisley, UK) and 
Abcam (Cambridge, UK) respectively. Anti-α -tubulin and hemin were from (Sigma-Aldrich (Poole, UK) and 
anti-GAPDH from Millipore (Feltham, UK). HO inhibitor zinc (II) protoporphyrin IX chloride (ZnPPIX) was 
from Frontier Scientific (Logan, UT).
Mice. All animals were studied according to the guidelines from Directive 2010/63/EU of the European 
Parliament. Hmox1−/− mice (back-crossed 10 generations into the C57BL/6 background) were originally gen-
erated by Dr S-F Yet (Pulmonary and Critical Care Division, Brigham and Women’s Hospital, Boston, MA). The 
colony was maintained by Hmox1+/− mating, under specific pathogen-free conditions following guidelines from 
the Animal User and Institutional Ethical Committees of the Instituto Gulbenkian de Ciência. Female C57BL/6 
mice were purchased from Harlan Laboratories (Oxford, UK) and housed under controlled conditions in microi-
solator cages with autoclaved bedding, and ethical approval from Imperial College London under UK Home 
Office Licence number PPL70/6722. Irradiated food and drinking water were available ad libitum.
Matrigel plug assay. Angiogenesis was quantified as previously described5,29. Female C57BL/6 mice (10 
weeks old) were anaesthetised with isoflurane and injected subcutaneously with Matrigel (BD Biosciences, San Jose, 
CA), along the abdominal midline. Matrigel (8.13 mg/ml) was mixed with heparin (64 U/ml), VEGF (40 ng/mL) 
or vehicle. In gene silencing studies 2 μ M murine siRNA (siHO-1 pool, siCyclin A1 pool, or control siRNA) was 
incorporated in the Matrigel and PBS added to a final volume of 0.5 ml. In gene over-expression studies, Ad-HO-1 
or Ad0 (1 × 109 ifu/ml) were combined with Matrigel preparations as described above. Plugs were harvested after 
7 days from CO2-euthanised mice, fixed in 4% (w/v) paraformaldehyde, transferred to 70% ethanol, embed-
ded in paraffin and processed for hematoxylin and eosin staining. Neovessels were identified by the presence of 
nucleated cells in the vascular wall surrounding a lumen containing erythrocytes. The area of the Matrigel plug 
occupied by neovessels was quantified using ImageJ 1.29 software (National Institutes of Health (NIH), Bethesda, 
MD) and expressed as a percentage of the total area in 5 separate fields of view using a 20x objective lens.
Human and murine cell culture. The use of human EC was approved by Hammersmith Hospitals Research 
Ethics Committee (ref. 06/Q0406/21). Human umbilical vein EC (HUVEC) and human dermal microvascular 
endothelial cell line HMEC-1 (a gift from Dr E. Ades, CDC Atlanta), were cultured as described30. Murine EC 
(MEC) were isolated from Hmox1−/− and Hmox1+/+ littermate controls as previously reported31,32.
Immunoblotting. Immunoblotting of EC lysates was performed as described previously33. To control for 
sample loading, membranes were re-probed with an α -tubulin or GAPDH Ab. Relative levels of protein expres-
sion were quantified using ImageJ.
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siRNA transfection. siRNA was introduced into EC using GeneFECTOR (3:50) (VennNova, Parkland, Fl). 
GeneFECTOR and siRNA (40 nM final) were diluted separately in Opti-MEM I (ThermoFisher Scientific, 
Runcorn, UK. Transfection solutions were added to HUVEC cultured in Opti-MEM I medium. After incuba-
tion for 6 h, culture medium was replaced with EBM2 medium (Lonza, Wokingham, UK) overnight and then 
with M199/10% FBS. Single sequence siRNA against human HO-1 (siHO-1 seq2) was purchased from Qiagen 
(Manchester, UK). The siRNA pools of 4 sequences against human HO-1, vimentin and cyclin A1 and murine 
HO-1 and cyclin A1 were from Dharmacon (Lafayette, CO). A non-targeting siRNA Silencer Negative Control 
#1 was purchased from Ambion (Austin, Texas). 3′ -end AlexaFluor 488-labelled siRNA against HO-1 and the 
AllStars Negative Control siRNA AlexaFluor 488 were from Qiagen.
Adenoviral infection. The recombinant adenovirus expressing Hmox1 (Ad-HO-1) and the Ad0 control ade-
novirus were amplified in human embryonic kidney 293A cells, purified and titrated as described32. HUVEC were 
infected by incubation with adenovirus in serum-free M199 for 2 h at 37 °C and maintained in M199 containing 
10% fetal FBS and 7.5 μ g/ml endothelial cell growth factor (Sigma-Aldrich). Optimal multiplicity of infection 
(MOI) for Ad-HO-1 was previously determined by immunoblotting32.
Proliferation, apoptosis and cell cycle assays. HUVEC proliferation was quantified using the Cell 
Proliferation BrdU ELISA (Roche Diagnostics, Burgess Hill, UK) according to the manufacturers’ instructions. 
EC were labelled with 10 μ M BrdU for 3 hours, fixed and denatured with FixDenat solution, and incubated with 
an anti-BrdU-peroxidase mAb for 90 min. Immune complexes were detected by tetramethyl-benzidine and quan-
tified using a plate reader measuring absorbance at 370 nm and a reference wavelength at 494 nm. In addition, 
proliferation was assessed by flow-cytometry using an anti-PCNA antibody. For cell cycle analysis HUVEC trans-
fected with HO-1 specific or control siRNA were treated with 25 ng/mL VEGF or vehicle for 16 h followed by fix-
ation in 70% ethanol and staining with a propidium iodide (PI) solution composed of 50 μ g/ml propidium iodide, 
20 U/ml RNase (both Sigma-Aldrich), 18 mg/ml EDTA, and 0.1% Triton X-100 for 45 min at 37 °C. Apoptotic 
cells were quantified by measuring the sub-G1 population by flow-cytometry.
Migration and tube formation assays. HUVEC monolayers were scratched and the migration path of 
the leading edge assessed by live cell imaging (LSM510 Meta; Zeiss, Oberkochen, Germany) and further analysis 
using ImageJ 1.29 software and the Ibidi Chemotaxis and Migration tool (Ibidi GmbH, München, Germany). 
Chemotatic behaviour of control or HO-1 siRNA-transfected EC was assessed using the μ -slide chemotaxis assay 
(Ibidi). HUVEC were cultured on collagen IV-coated μ -slides in EGM-2 supplemented with 10% FBS and allowed 
to adhere for 3 hours. One reservoir was filled with growth factor-free EBM/2% FBS and the second reservoir with 
VEGF-supplemented medium (25 ng/ml). Directional migration was assessed after 16 hours and tracked with the 
aid of time-lapse microscopy. Formation of tubular structures was studied on growth factor-reduced Matrigel. 
EC transfected with control or HO-1-specific siRNA were seeded onto Matrigel in growth factor-free EBM-2/2% 
FBS. Tube formation was assessed by phase-contrast microscopy after 16 hours and quantified using the ImageJ 
plugin NeuronJ (NIH).
Immunofluorescence. HUVEC cultured on glass coverslips were fixed in methanol for 15 min at − 20 °C, 
permeabilized with 0.5% Triton-X 100, and stained with anti-vimentin mAb overnight at 4 °C and Alexa Fluor 
568-labelled goat anti-mouse IgG1 for 1 hour. Nuclei were visualized with Draq 5 (Cell Signaling Technology, 
Danvers, MA). Coverslips were mounted onto glass slides and Z-stack projections captured by confocal 
microscopy.
In vitro adhesion assay. Control or HO-1 specific siRNA-treated HUVEC were labelled with 
5-chloromethylfluoresein diacetate (6.25 μ M) (Invitrogen Cell Tracker Green, Invitrogen, Paisley, UK) for 30 min 
and re-seeded at 20,000 cells per well of 96-well plates coated with gelatin or collagen type I (BD Biosciences) and 
cultured in EBM-2 media supplemented with VEGF (25 ng/ml) or vehicle for 40 min. Total cellular fluorescence 
was recorded using absorption and emission settings at 492 and 517 nm respectively, and bound EC quantified as 
a percentage of the total cells seeded.
Senescence-associated beta-galactosidase (SA-β-gal) staining. HUVEC (passage 2–4) were fixed 
with 0.5% glutaraldehyde/PBS and incubated with 20 mg/ml 5-bromo-4-chloro-3-indolyl β -D-galactosidase 
(X-gal) in N,N-dimethylformamide, 100 mM potassium hexacyano-ferrate (III) (K3[Fe(CN)6]) and 100 mM 
potassium hexacyano-ferrate (II) trihydrate (K3[Fe(CN)6])* 3H2O (all Sigma-Aldrich) in PBS for 24 hours at 37 °C. 
HUVEC cultured for >12 passages acted as a positive control, with senescent cells identified by phase-contrast 
microscopy.
Calpain activity. Control or HO-1 specific siRNA-transfected HUVEC were loaded with 30 μ M 7-amino- 
4chloromethycoumarin (tBoc-LM-CMAC; Invitrogen) in serum-free medium for 30 min prior to VEGF treat-
ment. Fluorescence was measured on a CyAN ADP analyzer (Beckman Coulter, High Wycombe, UK) using the 
Violet-1 filter (FL6).
Analysis of PCR Arrays. SABiosciences Human Cytoskeleton Regulators RT2 Profiler PCR Array (Qiagen) 
was used as per manufacturers’ instructions. HUVEC from 3 separate donors were transfected with HO-1 or 
control siRNA and exposed to VEGF for 16 hours before lysis in RLT Buffer. Lysate RNA was isolated using the 
RNeasy Mini Kit (Qiagen) and quantified by Nanodrop analysis. Ribosomal band integrity was determined on an 
Agilent 2100 BioAnalyzer, using an RNA 6000 Nano LabChip (Agilent Technologies, Santa Clara, CA.).
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Difference in-gel electrophoresis (DIGE) and mass spectrometry. HUVEC transfected with HO-1 
or control siRNA and exposed to VEGF for 16 hours were lysed with DIGE lysis buffer containing 8 M urea, 4% 
CHAPS, protease inhibitors and 30 mM Tris (pH = 8.5). Cell lysates were subjected to difference in-gel electro-
phoresis (DIGE) followed by protein identification using nanoflow liquid chromatography (LC) and tandem mass 
spectrometry. The samples were labelled with Cy3 or Cy5 (GE Healthcare, Amersham, UK) and 40 ug of proteins 
were mixed together with a Cy2-labelled pooled standard. Protein samples were mixed with 2x DIGE buffer (8 M 
urea, 2% DTT, 4% CHAPS, 2% pharmalytes 3–10 for IEF) and further diluted with rehydration buffer (8 M urea, 
0.5% CHAPS, 0.2% DTT, 0.2% pharmalytes, and trace bromophenol blue) to 450 ul. The samples were applied to 
IPG strips (18 cm, 3–10 NL, GE Healthcare) and rehydrated overnight. Strips were focused at 0.05 mA/IPG strip 
for 28 kVh at 20 °C overnight and equilibrated in buffer (6 M urea, 2% SDS, 30% glycerol, 50 mM Tris, pH = 8.8, 
trace bromophenol blue) with 10 mg/mL DTT for 15 min and with 48 mg/mL iodoacetamide for 15 min. The 
IPG strips were transferred to large format polyacrylamide gels (12% total acrylamide, 2.6% cross-linking) and 
underwent SDS-PAGE. Fluorescent images were acquired using an Ettan DIGE imager (GE Healthcare) and gels 
were silver-stained to locate differentially expressed protein spots. Fluorescent images were analysed by DeCyder 
software (version 7.0, GE Healthcare). Protein spots with fold change > 1.2 or < − 1.2 and p < 0.05 were excised 
manually. Selected spots were subjected to overnight in-gel tryptic digestion using a robot (ProGest, Digilab, 
Artisan Technology group, Champaign, IL). Tryptic peptides were separated by nanoflow LC (Ultimate 3000 
RSLCnano, ThermoFisher) on a reverse-phase C18 column (PepMap100, C18, 25 cm × 75 um) interfaced to a 
LTQ Orbitrap XL mass spectrometer (ThermoFisher) with full scan mass-to-charge (m/z) range of 400–1600 
followed by 6 data-dependent MS2 scans with dynamic exclusion enabled. A database search was performed 
using Mascot server (Matrix Science Ltd, London, UK) against a human database (UniProt/SwissProt 57.15, 
20266 protein entries) with the following parameters: precursor mass tolerance 10 ppm, fragment mass tolerance 
0.8 Da, carbamidomethylation on cysteine as fixed modification, oxidation on methionine as variable modifica-
tion, maximum 2 miss cleavages were allowed. Scaffold software (Proteome Software, Portland, OR) was used to 
validate MS/MS-based peptide and protein identity with the following filters: peptide probability > 95%, protein 
probability > 99%, minimum number of peptides per protein > = 234. Differentially expressed proteins were ana-
lyzed using Database for Annotation, Visualization and Integrated Discovery (DAVID) Bioinformatics Resources 
6.7 (National Institute of Allergy and Infectious Diseases, NIH) and grouped according to gene ontology (GO).
Statistics. Numerical data are presented as the mean of individual experiments ± standard error (SEM). 
Data were grouped according to treatment and analysed using GraphPad Prism Software (San Diego, CA, USA). 
Differences between treatments were evaluated using either an unpaired Student’s t-test, or a one-sample t-test for 
comparison of two samples. For evaluation of three or more samples the one-way analysis of variance (ANOVA) 
was used. A Bonferroni correction was used to correct for multiple comparisons. Differences were considered 
significant at a P < 0.05.
Results
Role of HO-1 in VEGF-induced EC proliferation and apoptosis. To investigate the role of HO-1 in 
VEGF-mediated endothelial proliferation and resistance to apoptosis, a gain and loss of function approach using 
specific siRNA-mediated depletion and adenoviral over-expression was adopted. To validate HO-1 siRNAs, 
hemin treatment of HUVECs was used to induce HO-1 protein. A single HO-1 siRNA oligonucleotide (Seq 2) and 
a pool of 4 targeted siRNAs reduced HO-1 by 90%, while having no effect on HO-2 (Supplementary Figure 1A,B 
and data not shown). Infection of EC with Ad-HO-1 increased HO-1 protein after 24 h, maximal at an MOI of 100 
ifu/cell (Supplementary Figure 1C).
Endothelial proliferation was quantified by BrdU incorporation and flow-cytometric analysis of PCNA. The 
presence of HO antagonist ZnPPIX exerted a concentration-dependent inhibitory effect on VEGF-induced 
HUVEC proliferation. A 7-fold increase in proliferation was reduced to only 1.5–2-fold by ZnPPIX (20 μ M) 
(Supplementary Figure 1D). VEGF treatment for 48 h increased EC PCNA expression by up to 30%, a response 
completely attenuated by HO-1 depletion (p < 0.05) (Fig. 1A). Adenoviral over-expression of HO-1 also increased 
EC proliferation by up to 3-fold and further increased the VEGF-induced proliferative response from 6- to 8-fold, 
when compared with the control adenovirus (Fig. 1B).
Next, an MTT cell survival assay was used to investigate the role of HO-1 in VEGF-mediated cytoprotection. 
First, both HO inhibitor ZnPPIX and HO-1 silencing reduced the basal number of EC by up to 50%. VEGF 
increased the EC number by 50–70% at 24 h and this response was significantly attenuated by ZnPPIX and HO-1 
siRNA (p < 0.05) (Supplementary Figure 1E and Fig. 1C). Serum starvation (grey bars) reduced EC survival by 
75%, a response almost completely reversed by the presence of VEGF. However, the changes in VEGF-mediated 
cytoprotection seen following the inclusion of ZnPPIX or the depletion of HO-1 failed to reach significance, so 
distinguishing the protective response from EC proliferation (Supplementary Figure 1E and Fig. 1C). These data 
were confirmed using propidium iodide labelling followed by flow-cytometric analysis of the sub-G1 apoptotic 
cell population. When compared to serum-starved control siRNA-transfected EC, VEGF reduced apoptosis by 
50%, while HO-1 depletion increased apoptosis by 1.5-fold. However, as before, VEGF-mediated cytoprotec-
tion was not attenuated by HO-1 silencing (Fig. 1D). In support of these findings, analysis of VEGF-inducible 
anti-apoptotic genes showed that neither the 7-fold induction of A1, nor the 3-fold induction of Bcl-2 in 
VEGF-treated HUVEC transfected with control siRNA was impaired by HO-1 silencing (Fig. 1E,F).
HO-1 influences directional migration of EC. Directional migration of EC is an essential component 
of angiogenesis. A scratch assay was employed to determine the role of HO-1 in this process. To identify and 
track individual HUVEC, AlexaFluor488-labelled HO-1 siRNA (seq2AF488) or control siRNA (CTLAF488) was 
used (Supplementary Figure 1B). VEGF increased the linear distance between the starting and end points of the 
www.nature.com/scientificreports/
5Scientific RepoRts | 6:29417 | DOI: 10.1038/srep29417
Figure 1. siRNA-mediated HO-1 depletion abrogates VEGF-induced HUVEC proliferation. (A) HUVEC 
were transfected with control siRNA (CTL) or HO-1-specific siRNA prior to culture in the presence or absence of 
VEGF (25 ng/ml) for 48 h. Proliferation was quantified by flow-cytometric analysis of PCNA staining. (B) HUVEC 
were left uninfected or infected with the Ad0 control adenovirus or AdHO-1 (multiplicity of infection (MOI) 100 
ifu/cell). EC were then cultured in the absence or presence of VEGF for 48 h and proliferation quantified by BrdU 
ELISA. (C) HUVEC were treated with vehicle alone (dotted line) or transfected with control siRNA (CTL) or 
HO-1 specific siRNA (seq2 or 4 pooled sequences (pool)). Cells were cultured in M199 medium/10% FCS (white 
bars) or serum-starved in M199/0.1% BSA in the absence or presence of VEGF (25 ng/ml) for 48 h (dark bars). 
Cell number was assessed by MTS-assay. (D) HUVEC were transfected with control (CTL) or pooled HO-1 siRNA 
oligos (HO-1) as above prior to culture with or without VEGF and serum starvation. Sub-G1 apoptotic EC were 
identified by propidium iodide staining and quantified by flow-cytometry, with data expressed as a percentage 
of the apoptosis seen in control siRNA-treated serum-starved cells. (E,F) HUVEC were transfected with control 
or pooled HO-1 siRNA (HO-1) and cultured in the absence or presence of VEGF for 48 h, with (E) Bcl-2 protein 
analysed by immunoblotting and quantified by densitometry, and (F) A1 mRNA quantified by qRT-PCR. Data are 
presented as mean ± SEM (n ≥ 4 experiments), * p < 0.05, * * p < 0.01, * * * p < 0.001, ns = not significant.
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migration pathway (Euclidean distance) from 139 ± 9.8 to 183 ± 12.5 μ m (p < 0.01). VEGF-enhanced HUVEC 
migration was reduced by HO-1 depletion to 111 ± 7.4 μ m (p < 0.001) (Fig. 2A), with comparable results seen 
with HMEC (Supplementary Figure 2A). Plotting the individual paths tracked by the transfected cells showed 
that VEGF treatment increased migration in the direction of the scratch (Fig. 2B). HO-1 depletion inhibited this 
effect, with cell migration markedly restricted (Fig. 2C). Although over-expression of HO-1 enhanced cell migra-
tion to a similar extent to VEGF (177 ± 8.9 μ m), in combination no synergistic or additive effect was observed 
(184 ± 12.6 μ m) (Fig. 2D).
The Ibidi μ -slide chemotaxis assay was used to assess the role of HO-1 in mediating chemotactic migra-
tion of EC. HUVEC were transfected with seq2AF488 or control CTLAF488 and migration towards VEGF or con-
trol media containing reservoirs was captured by time-lapse microscopy. Single cell tracking of fluorescent cells 
towards the stimulus is shown in black, and away from the stimulus in red (Fig. 2E,F). The significant majority 
of control-transfected cells migrated towards VEGF, whereas HO-1 depletion impaired chemotaxis, decreasing 
migration towards VEGF by 40% (p < 0.001) (Fig. 2G).
Figure 2. HO-1 inhibition impairs EC migration in vitro. HUVEC were transfected with 3′ -AlexaFluor488-
labelled control siRNA (CTLAF488) or HO-1-specific siRNA (seq2AF488) and (A) Confluent EC monolayers 
were scratched and migration (Euclidean distance) was assessed by live cell imaging in the absence or presence 
of VEGF (25 ng/ml) for 16 h. (B,C) Illustrate directional migration, with images representative of n = 3 
experiments, (B) Ctl siRNA and (C) HO-1 siRNA, with histograms plotting migration of individually tracked 
cells. Bar = 50 μ m. (D) HUVEC were infected with Ad0 or AdHO-1 (MOI 100) and cultured for 16 h. Confluent 
cell monolayers were scratched and migration assessed in the absence or presence of VEGF as above for 16 h. 
(E,F) HUVEC were transfected with CTLAF488 (E), or (F) HO-1 siRNA (seq2AF488) and re-seeded onto 
collagen IV-coated Ibidi chemotaxis μ -slides. The upper reservoir contained EBM-2 medium with 25 ng/ml 
VEGF and the lower reservoir plain EBM-2. Tracking of fluorescent transfected cells was captured by time-lapse 
microscopy every 15 mins for 16 h. Migration paths along the VEGF gradient are shown in black and away in 
red. Plots are representative of 3 experiments and (G) shows quantitative data presented as mean ± SEM (n = 3). 
Migration was quantified using ImageJ software (Manual Tracking, Chemotaxis and Migration tool). Data are 
presented as mean ± SD (n ≥ 3 experiments), * p < 0.05, * * p < 0.01, * * * p < 0.001.
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HO-1 inhibition impairs EC tubule formation. Formation of tubules on Matrigel was used as a func-
tional end-point for changes in EC migration. Exposure of control siRNA-transfected HUVEC to VEGF accel-
erated tube formation and increased average tube length by 34% from 469 ± 19.3 to 629 ± 26.7 pixels. HO-1 
depletion reversed this VEGF response in HUVEC, reducing tube length to a minimum of 387 ± 14.2 (Fig. 3A,B), 
with the same effect observed with HMEC (Supplementary Figure 2B). Although murine EC isolated from 
Hmox1−/− mice and wild-type littermates formed tubular networks on Matrigel, the former were less well differ-
entiated. Furthermore, WT EC responded to VEGF with increased tube length of 25%, while Hmox1−/− tubules 
remained shorter 69 ± 2.3 vs 105 ± 7.9 μ m and less well formed, with clusters of EC observed. They also failed to 
respond to VEGF (72 ± 1.9 μ m) (Fig. 3C,D).
HO-1 depletion predisposes to cell cycle arrest. In light of the EC migration data obtained, a PCR 
array incorporating 84 genes involved in cytoskeletal regulation was initially chosen to investigate downstream 
effectors of HO-1 in VEGF-driven responses. Pooled HUVEC, derived from 3 donors, were transfected with 
control or HO-1 siRNA and treated with VEGF for 16 h prior to analysis. The expression of four transcripts was 
increased > 2.0-fold in HO-1-depleted EC: Actin related protein 2/3 complex, subunit 2, Citron (rho-interacting, 
serine/threonine kinase 21), Fascin homolog 2, actin-bundling protein and Protein phosphatase 1, regulatory 
(inhibitor) subunit 12B (Supplementary Table 1). A single gene, the positive cell cycle regulator cyclin A1, was 
found to be significantly down-regulated by HO-1 depletion (fold change 0.44). As this latter response suggested 
cyclin A1 is positively regulated by HO-1, it was selected for further analysis.
First, the effect of HO-1 depletion on cell cycle progression was analysed. In response to VEGF, control 
siRNA-transfected cells progressed from G0/G1 to S-phase as indicated by an increase in DNA content from 
12.75 ± 0.54% to 15.75 ± 0.81%. This response was significantly diminished by HO-1 depletion, both in the 
absence and presence of VEGF, resulting in S-phase DNA distributions of 7.95 ± 0.43% and 11.27 ± 0.62% respec-
tively (Fig. 4A). To investigate a potential role for premature cellular senescence, EC were stained for SA-β -gal 
activity. Prolonged culture of HUVEC for 12 passages resulted in an 80% increase in SA-β -gal positive cells in the 
absence and presence of VEGF, when compared to cells cultured for 4 passages. However, HO-1 silencing had no 
significant effect on EC senescence (Supplementary Figure 3), suggesting that cell cycle arrest in HO-1-depleted 
cells is not the result of premature senescence. Next, the induction of cyclin A1 by VEGF and the inhibition of this 
response by HO-1 silencing was further validated (Fig. 4B). Additional study of cyclins not included in the PCR 
array showed that cyclin E1 responded similarly to A1 (Fig. 4C), while cyclin B1 and D1 were induced by VEGF 
but not affected by HO-1 depletion (Supplementary Figure 3B,C).
Figure 3. HO-1 inhibition impairs directional migration of EC. (A) HUVEC were transfected with control 
siRNA (CTL), HO-1 siRNA (seq2) or pooled HO-1 siRNAs (pool). Cells were seeded onto growth factor-
reduced Matrigel in the presence or absence of VEGF for 16 h. Images from five fields per view were captured, 
and (B) tube length was quantified using ImageJ software (NeuronJ). (C) Murine EC from Hmox1−/− mice 
or Hmox1+/+ littermate controls were seeded onto growth factor-reduced Matrigel in the presence or absence 
(UT) of VEGF for 16 h. Images from five fields per view were captured and (D) tube length quantified using 
ImageJ. Pictures are representative of 3 experiments (Bars = 50 μ m). Data are presented as mean ± SEM (n = 3 
experiments), * p < 0.05, * * p < 0.01, * * * p < 0.001.
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Relationship between cyclin A1, Cdk2 and HO-1. Cyclins A1 and E1 form complexes with and regu-
late the activity of cyclin-dependent kinase2 (Cdk2). Cdk2 was increased in VEGF-treated HUVEC, a response 
attenuated by specific depletion of HO-1 (Fig. 4D). This may in turn reflect inhibition by p27, as analysis of the 
innate Cdk2 inhibitors p21 and p27 showed that, while VEGF treatment had no significant effect on p21 or p27 
expression per se, HO-1 depletion led to a modest but significant increase in p27 (Fig. 4E), a response not seen 
for p21 (not shown).
Migrating EC were studied to investigate the functional relationship between HO-1, cyclin A1 and Cdk2 
activity. As above, HO-1 depletion inhibited the VEGF-induced increase in the Euclidean distance (Fig. 5A) and 
the induction of cyclin A1 (Fig. 5B). Moreover, cyclin A1 levels were significantly reduced in the HO-1 depleted 
EC by 50–75% (Fig. 5B). Phosphorylation of retinoblastoma protein (pRb) at Thr821 is induced by active cyclin 
A1/Cdk2 complexes and is thereby a measure of Cdk2 activity35. Following 16 h VEGF treatment, pRb was 
increased by 80% in migrating control siRNA-transfected HUVEC, indicative of active Cdk2. Phosphorylation 
was abrogated by HO-1 silencing, revealing reduced Cdk2 activity and suggesting a link between cell cycle 
Figure 4. HO-1-deficiency results in endothelial cell cycle arrest. (A) Control siRNA (siCTL)-transfected 
or pooled siHO-1-transfected HUVEC were left untreated or treated with 25 ng/ml VEGF for 48 h prior 
to propidium iodide staining and flow-cytometric analysis of DNA distribution. Data is presented as 
mean ± SEM (n = 3 experiments), * p < 0.05 vs siCTL, δp < 0.05 vs siCTL + VEGF. (B) HUVEC were exposed to 
geneFECTOR alone (GF) or transfected with control siRNA (CTL) or pooled HO-1 siRNA (HO-1). Cells were 
cultured in the presence or absence of VEGF for 24 h prior to mRNA quantification by qRT-PCR of (B) cyclin 
A1, (C) cyclin E1, (D) cyclin-dependent kinase 2 (cdk2) or (E) p27. Data are presented as mean ± SEM (n = 3 
experiments), * p < 0.05, * * p < 0.01. δ δ p < 0.01 vs untreated siCTL-transfected cells.
www.nature.com/scientificreports/
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regulation and HO-1-driven endothelial migration (Fig. 5C). To explore these observations in vivo, Matrigel, 
supplemented with VEGF and heparin and containing control siRNA or previously validated siRNAs against 
murine HO-1 or cyclin A1 (Supplementary Figure 3D,E), was injected sub-cutaneously in female C57Bl/6 mice. 
After 7 days VEGF supplementation had significantly increased the vascularisation of Matrigel plugs contain-
ing control siRNA (from 2.2 ± 0.4 to 17.25 ± 1.57 neovessels per high power field (hpf)), while depletion of 
HO-1 or cyclin A1 attenuated neovessel development in response to VEGF, reducing neovessels to 12.55 ± 1.81 
and 9.45 ± 1.50/hpf respectively (Fig. 6A–F and K). Inclusion of Ad-HO-1 in Matrigel plugs was sufficient to 
enhance angiogenesis by more than 2-fold to 23.42 ± 3.15/hpf when compared to a control virus (8.89 ± 2.22/hpf) 
(p < 0.01). Furthermore, the presence of Ad-HO-1 overcame the inhibitory effect of A1 depletion (20.67 ± 2.18/
hpf) (Fig. 6G–K), suggesting the existence of additional HO-1-regulated genes involved in angiogenesis.
HO-1 depletion alters VEGF-induced calpain activity and vimentin cleavage. To identify further 
HO-1 targets capable of affecting endothelial cell function, the proteome of HUVEC transfected with HO-1 or 
control siRNA and exposed to VEGF was compared. Cy3 and Cy5-labelled proteins were separated by difference 
in-gel electrophoresis (Supplementary Figure 4). Subsequent image analysis revealed 29 proteins with a signif-
icant difference (p < 0.05, fold change >1.2 or <− 1.2) in signal intensity between control and HO-1-depleted 
cells (Supplementary Table 2 shows all identified proteins and ratio/p-value). These altered proteins were ana-
lysed using DAVID and grouped according to gene ontology, focusing on cytoskeletal proteins, intermediate 
filaments and proteins regulating cell structure and motility (Supplementary Table 3). A common hit amongst all 
Figure 5. Cyclin A1 is reduced in migrating HO-1-deficient EC. HUVEC were transfected with CTLAF488 
or HO-1 siRNA (seq2AF488). Monolayers were scratched and treated with vehicle alone or VEGF (25 ng/ml) 
for 16 h (A) Migration was quantified by live cell imaging using ImageJ. EC were then harvested, lysed and 
immunoblotted for: (B) cyclin A1 and (C) retinoblastoma protein (pRb) and phospho-pRbpT821. The histograms 
show corresponding densitometry data corrected for the GAPDH loading control and with phospho-pRb 
expressed relative to total pRb. Data are presented as mean ± SEM (n = 3 experiments), * p < 0.05, * * p < 0.01;  
* * * p < 0.001.
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these groups was the intermediate filament vimentin, which plays a role in cell adhesion and migration and has 
been implicated in the maintenance of angiogenic sprouting and vascular endothelial integrity36,37. Vimentin was 
therefore selected for further study.
Initial immunoblotting demonstrated no detectable difference in total vimentin between control and 
HO-1-depleted EC (Fig. 7A), suggesting that the changes in vimentin intensity seen on the 2D gels may reflect its 
size or phosphorylation status. VEGF induces vimentin cleavage via activation of calpains and further immunob-
lotting analysis revealed multiple 40–50kDa vimentin bands in VEGF-treated HUVEC (Fig. 7B). This response 
was not altered by inclusion of a lambda phosphatase (Supplementary Figure 5A), suggesting cleaved vimentin 
accounted for the 40–50 kDa bands as opposed to differential vimentin phosphorylation. Importantly, HO-1 
depletion significantly reduced vimentin cleavage, with fewer lower intensity bands seen (Fig. 7B). Subsequent 
analysis of HUVEC calpain activity revealed a significant increase after 60–90 mins of VEGF treatment (maxi-
mally 60 ± 3.9% at 60 mins, and 93 ± 5.7% above control at 90 mins). This response was partially but significantly 
attenuated by HO-1 depletion to 39 ± 4.3% at 60 mins and 70 ± 3.7% above control at 90 mins (p < 0.05) (Fig. 7C). 
Next, to determine whether activation of HO-1 itself can induce calpain activity, HUVEC were treated with a 
potent HO-1 agonist hemin for 2 hours. As shown in Fig. 7D, hemin led to a concentration-dependent increase in 
calpain activity, so reinforcing the link between HO-1 and calpain activity.
HO-1 depletion affects vimentin distribution and endothelial adhesion. Next, vimentin filament 
assembly was studied to investigate the implications of HO-1 depletion on vimentin function. Confocal z-stack 
analysis demonstrated a punctate vimentin staining pattern in control siRNA-transfected EC, consistent with 
vimentin particles and short filaments. Exposure of these cells to VEGF resulted in the development of a wide-
spread dense vimentin filament network (Fig. 8A,B). Whilst there was no alteration in the vimentin staining 
pattern or cell area in untreated cells following HO-1-depletion, changes in response to VEGF were significantly 
attenuated (Fig. 8C–E). VEGF increased cell area from 17.7 ± 1.5 × 103 to 31.3 ± 3.7 × 103 pixels2 (p < 0.01), with 
the latter area reduced to 21.1 ± 2.1 × 103 pixels2 in HO-1-depleted cells exposed to VEGF (p < 0.05).
Vimentin regulates EC integrin function and cell adhesion, key components of cell migration38. To 
investigate the potential role of HO-1 and vimentin in EC adhesion, HUVEC loaded with fluorescent dye 
5-chloromethylfluorescein diacetate were seeded on to either gelatin or collagen type-1 coated plastic ± VEGF. 
No effect of HO-1-depletion on β 1 integrin-dependent adhesion to collagen was seen (not shown). In contrast, 
Figure 6. Silencing of cyclin A1 impairs angiogenesis in vivo. Female C57BL/6 mice (10 weeks old, n = 3 
per treatment) were injected with Matrigel preparations containing: (A) vehicle control, (B) VEGF (40 ng/ml) 
with 2 μ M control siRNA (CTL), (C,D) VEGF with murine HO-1 siRNA (HO-1), (E,F) VEGF with murine 
CycA1 siRNA (CycA1). (A,B,C,E) 10x magnification, bar = 50 μ m (D,F) 20x magnification, bars = 100 μ m. In 
(G–J) Matrigel plugs contained (G) Ad0 control, (H) AdHO-1, (I) AdHO-1 + Ctl siRNA, (J) AdHO-1 + CycA1 
siRNA. Representative images (10x magnification, bars = 50 μ m). (K) Area occupied by neovessels quantified 
using ImageJ software. Data are presented as mean ± SEM (n = 3 experiments). * p < 0.05, * * p < 0.01;  
* * * p < 0.001.
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despite no difference in the surface expression of α vβ 3 (Supplementary Figure 5B), there was a reduction in adhe-
sion to gelatin of 34% and 41% in the absence and presence of VEGF respectively (p < 0.05), suggesting impaired 
integrin activation and α vβ 3-dependent adhesion (Fig. 8F). Together these data indicate a close relationship 
Figure 7. Calpain activation by VEGF is inhibited in HO-1-depleted HUVEC. (A,B) HUVEC were treated 
with geneFECTOR (GF) alone or transfected with control siRNA (CTL) or pooled HO-1 siRNAs (HO-1) 
prior to treatment with VEGF (25 ng/ml) or vehicle for 16 h and: (A) HO-1 and vimentin were quantified by 
immunoblotting, and in (B) Vimentin and HO-1 were assessed by Phos-tag SDS-PAGE and immunoblotting. 
Changes in expression were quantified by densitometry corrected for GAPDH. (C) HUVEC were either treated 
with GF alone or transfected with CTL or HO-1 siRNAs (seq2 or pool) for 24 h. Cells were pre-loaded with 
calpain substrate tBoc-LM-CMAC prior to treatment with VEGF or vehicle. In (D) HUVEC were pre-loaded 
with the calpain substrate prior to treatment with hemin (0.2 or 2 μ M) for 2 h. Calpain activity was assessed by 
flow-cytometry. Data are presented as the mean fluorescence intensity (MFI) ± SEM (n = 3 experiments) 
* p < 0.05,* * p < 0.01, * * * p < 0.001.
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between HO-1, calpain activity and vimentin function, with loss of HO-1 resulting in impaired cytoskeletal 
structure, EC adhesion and migration. Finally, in light of the findings shown in Fig. 6 suggesting the existence of 
additional HO-1-regulated genes involved in angiogenesis, we investigated the role of vimentin. HUVEC were 
depleted of vimentin using siRNA prior to adenoviral over-expression of HO-1. While cell proliferation induced 
by HO-1 was unaffected by control siRNA, silencing of vimentin abrogated the HO-1-mediated proliferative 
response (p < 0.001).
Discussion
HO-1 plays a central role in angiogenesis driven by VEGF and SDF1-α . Both cytokines increase HO-1 expression 
and activity5,16,20,22, with the induction of HO-1 dependent upon nuclear translocation of Nrf224. However, a key 
challenge remains, namely identification of HO-1 target genes, and this was the predominant aim of the current 
study. Using gain and loss of function approaches we have identified cyclin A1, cyclin E1 and vimentin as down-
stream targets of HO-1 during VEGF-driven angiogenic responses in the vascular endothelium (Fig. 9). HO-1 
depletion inhibited human EC proliferation, tubule formation and directional migration along a VEGF chemotac-
tic gradient; a phenotype reversed by HO-1 over-expression. Silencing of HO-1 in VEGF-treated cells resulted in 
endothelial cell cycle arrest associated with depletion of cyclins A1 and E1, increased p27 expression and reduced 
Figure 8. Vimentin filament assembly and EC adhesion is impaired by HO-1-depletion. HUVEC, 
transfected with (A,B) CTLAF488 or (C,D) HO-1 siRNA seq2AF488, were seeded onto gelatin-coated coverslips 
in the absence (UT) or the presence of 25 ng/ml VEGF for 16 h, prior to fixation and vimentin staining. Nuclei 
were stained with Draq5. Immunofluorescence was analyzed by confocal microscopy. Representative images are 
shown, 63x magnification, bar = 50 μ m. (E) Cell area was quantified using ImageJ (n = 15). (F). HUVEC treated 
with geneFECTOR (GF) alone or transfected with control (CTL) or HO-1 siRNA (seq2) were labelled with 
5-chloromethylfluorescein diacetate (6.25 μ M) and seeded onto gelatin-coated 96-well plates in the absence 
(UT) or the presence of VEGF for 40 min. Fluorescence was measured pre- and post-washing, with adhesion 
expressed as the percentage of bound cells relative to the total number seeded. (G). HUVEC were left untreated 
or transfected with control or vimentin siRNAs. Cells were then left untreated (Control) or infected with Ad0 
and AdHO-1 for 24 hrs. Cell proliferation was quantified by BrdU ELISA. Data are presented as mean ± SEM 
(n = 3–5 experiments), * p < 0.05, * * * p < 0.001.
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cdk 2 activity. In Matrigel plug assays, HO-1 or cyclin A1 siRNA inhibited VEGF-driven angiogenesis. Proteomic 
analysis identified vimentin as a downstream target of HO-1 in VEGF-treated human EC. VEGF-induced cal-
pain activity and subsequent cleavage of vimentin was abrogated by HO-1 siRNA. VEGF-mediated changes in 
vimentin filament assembly and α vβ 3-dependent adhesion of EC were also attenuated, while vimentin-depletion 
abrogated HO-1 driven EC proliferation.
In previous studies, retroviral over-expression of HO-1 in EC enhanced expression of cyclins A1 and E1, 
increasing proliferation and the percentage of cells in the G1 phase of the cell cycle39. The cyclin-dependent kinase 
inhibitors p21 and p27 were decreased by over-expression14,39. We have now shown that induction of cyclins A1 
and E1 by VEGF requires HO-1, and that HO-1 depletion results in cell cycle arrest in human EC. Of note, cyclin 
A1 has also been linked with VEGF-synthesis in prostate cancer40. Thus, we propose that positive feedback and 
endogenous amplification between VEGF and HO-1 in EC23 is driven by a VEGF-HO-1-cyclin A1-VEGF feed-
back loop. During inflammation this mechanism is important for vascular homeostasis, angiogenesis and tissue 
repair. However, in another context, such as prostate or lung carcinomas, the feedback loop may contribute to the 
link between HO-1 activity, carcinogenesis, tumour growth and metastasis41–43.
Cyclin A1 has also been implicated in EC migration, a critical step in angiogenesis. Contact-inhibited EC 
exhibit low-levels of cyclin A1 mRNA and protein44,45, with reduced cyclin A1, cyclin E1 and cdk2 kinase activity 
reported44. Following scratch injury, exposure of EC to VEGF led to cyclin A1 induction and an increase in cdk2 
activity, as indicated by enhanced phosphorylation of RB protein (Fig. 5). Thus, reduced cdk2 activity represents 
a likely mechanism for the inhibition of VEGF-mediated EC proliferation and migration seen in HO-1-depleted 
HUVEC. HO-1 silencing coincided with a fall in cyclin A1 and E1 and an increase in the inhibitory regulator p27, 
moving the cells back towards the quiescent phenotype observed following contact-inhibition. In vivo analyses 
revealed a role for HO-15 and cyclin A1 in VEGF-driven neovessel development. The inhibitory effect of cyclin 
A1 siRNA was reversed by HO-1 over-expression. This outcome may reflect incomplete depletion of cyclin A1 by 
siRNA in this setting. Alternatively, the presence of AdHO-1 may upregulate cyclin E1 or other pro-proliferative 
target genes, increase VEGF synthesis by EC or infiltrating monocytes, and/or drive additional pathways such as 
those regulated by SDF-1α .
Proteomic analysis sought additional HO-1 targets important for VEGF-driven angiogenesis, with vimentin 
emerging as a potential candidate. Vimentin is a highly conserved intermediate filament family protein, abundant 
in EC and mesenchymal cells. Dynamic interactions between vimentin, and actin-containing microfilaments and 
Figure 9. Cyclin A1, E1 and vimentin are downstream targets of HO-1. VEGF treatment of endothelial 
cells activates HO-1-dependent migration, proliferation and angiogenesis in vitro and in vivo. Microarray and 
proteomic analyses revealed cyclin A1, cyclin E1 and vimentin as downstream targets of HO-1. VEGF induced 
an HO-1-dependent increase in cdk2 kinase and calpain activity. These changes increased cell cycle progression 
and vimentin cleavage respectively. The role of HO-1 was established using specific siRNAs and HO-1 agonists. 
Similarly the importance of both cyclin A1 and vimentin in pro-angiogenic effects of VEGF and HO-1 activity 
were demonstrated by cyclin A1 and vimentin gene silencing.
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tubules stabilises cell structure. Beyond this, the study of vimentin-deficient mice has revealed novel functions 
in the vascular endothelium including maintenance of monolayer integrity, control of leukocyte trafficking and 
angiogenesis37,46,47. A central component is the role of vimentin in cell migration. Vimentin regulates cell-cell 
contact and adhesion through an association with hemidesmosomes, and via control of integrin function. In 
EC, vimentin interacts with integrin α vβ 3 in vimentin-associated matrix adhesions (VAMs)48. VAMs are actively 
assembled at the forefront of migrating cells and are disrupted by siRNA depletion of vimentin which leads to loss 
of cell adhesion49. In fibroblasts and vascular smooth muscle cells vimentin plays a central role in cell motility50,51.
Compared to control transfected cells, HO-1-depleted EC exhibited reduced adhesion to gelatin and impaired 
migration. The VEGF-induced switch from non-filamentous particles/short vimentin filaments to long, mature 
and peripheral filaments was attenuated by HO-1 silencing. Although rapid phosphorylation-dephosphorylation 
events play an important role in the regulation of vimentin filament distribution, no change in vimentin phos-
phorylation following HO-1 depletion was detected. To explore this further, we turned to the recent report that 
growth factor-induced calpain activation results in vimentin cleavage and relocalisation to the EC periphery, a 
response required for angiogenic sprouting36. Calpains are calcium-dependent cysteine proteases. They control 
cell migration through cleavage of actin regulatory proteins and participate in cell cycle regulation52,53. HO-1 
depletion attenuated VEGF-induced calpain activity and the associated cleavage and redistribution of vimentin 
filaments. Furthermore, pharmacological activation of HO-1 by hemin proved to be a potent inducer of calpain 
activity. We propose that loss of this close association between calpain, vimentin and HO-1 is a significant factor 
in the inhibition of cell migration observed in HO-1 deficient EC.
Importantly silencing of vimentin attenuated the pro-proliferative effect of HO-1 over-expression in HUVEC. 
The suggestion of a relationship between HO-1 activity and vimentin is supported by phenotypic similarities 
between the knockout mice. Hmox1−/− mice exhibit endothelial dysfunction, defective endothelial progenitor 
homing, reduced neovascularisation during wound healing and attenuated re-endothelialisation of the retinal vas-
culature following ischaemic injury16,17,54. Likewise, vimentin-deficient animals suffer impaired hypoxia-induced 
retinal neovascularisation, defects in endothelial barrier function and poor wound healing, which are associated 
with dysregulated granulation tissue generation, a process requiring angiogenic sprouting37,46,47.
In conclusion, the role of HO-1 during angiogenesis is context-dependent, important and offers therapeutic 
opportunities. However, a detailed understanding of the specific pro- and anti-angiogenic effects of HO-1, its 
enzymatic products and downstream target genes in regulating the the angiogenic cascade, for example during 
wound healing or in pathologies such as chronic inflammatory disease or neoplasms, is essential if therapeutic 
targeting is ever to be achieved safely2,55.
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